<DOC>
	<DOCNO>NCT01965145</DOCNO>
	<brief_summary>The objective study demonstrate superiority gevokizumab compare placebo top current standard care reduce risk Behçet 's disease uveitis exacerbation</brief_summary>
	<brief_title>Efficacy Gevokizumab Treatment Patients With Behçet 's Disease Uveitis ( EYEGUARD™-B )</brief_title>
	<detailed_description>A randomized , double-masked , placebo-controlled study efficacy gevokizumab treatment patient Behçet 's disease uveitis</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Behçet 's disease diagnosis fulfil International Study Group Classification Criteria . History Behçet 's disease uveitis ocular involvement posterior segment . Patients stable background treatment oral corticosteroid least one immunosuppressive drug . Male female , age ≥18 ( legal age majority country ) selection For subject reproductive potential , willingness use highly effective contraceptive measure Infectious uveitis , uveitis due cause Behçet 's disease . Monocular vision Presence severe cataract severe posterior capsular opacification . Contraindication mydriasis presence posterior synechiae . Active TB disease . History severe allergic anaphylactic reaction monoclonal antibody History malignancy within 5 year prior Selection . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>